Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 4 sources
Summary
The documented use of bezuclastinib is investigational. SUMMIT Part 2 evaluated 100 mg daily with best supportive care in nonadvanced SM with inadequate symptom control despite at least two anti-mediator therapies. Expanded-access protocols are described for eligible people with SM, subject to protocol-specific criteria. These trial and expanded-access arrangements do not constitute an approved routine-care indication.